Evidence map›Paper›PMID 28094869›Full record

ArticleExperimental dermatology2017

Loss of FAS/FASL signalling does not reduce apoptosis in Sharpin null mice.

Christopher S Potter, Kathleen A Silva, Victoria E Kennedy, Timothy M Stearns, Harm HogenEsch, John P Sundberg

Open access · bronzeAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental dermatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Christopher S PotterThe Jackson Laboratory, Bar Harbor, ME, USA.
Kathleen A SilvaThe Jackson Laboratory, Bar Harbor, ME, USA.
Victoria E KennedyThe Jackson Laboratory, Bar Harbor, ME, USA.
Timothy M StearnsThe Jackson Laboratory, Bar Harbor, ME, USA.
Harm HogenEschDepartment of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, IN, USA.
John P SundbergThe Jackson Laboratory, Bar Harbor, ME, USA.
Jackson Laboratory · USPurdue University West Lafayette · US

Funding

Shared Resource ManagementP30CA034196 · NCI · JACKSON LABORATORY · PI William Carl Skarnes · 1985 to 2026
$61.9M
Cpdm: Cloning a Gene That Regulates Eosinophil FunctionR01AR049288 · NIAMS · JACKSON LABORATORY · PI BOWCOCK, ANNE MARY, HOGENESCH, HARM · 2004 to 2016
$5.9M
NCI NIH HHS P30 CA034196NIAMS NIH HHS R01 AR049288
6 · The paper itself

Abstract

Mice with mutations in SHANK-associated RH domain interactor (Sharpin) develop a hypereosinophilic auto-inflammatory disease known as chronic proliferative dermatitis. Affected mice have increased apoptosis in the keratinocytes of the skin, oesophagus and forestomach driven by extrinsic TNF receptor-mediated apoptotic signalling pathways. FAS receptor signalling is an extrinsic apoptotic signalling mechanism frequently involved in inflammatory skin diseases. Compound mutations in Sharpin and Fas or Fasl were created to determine whether these death domain proteins influenced the cutaneous phenotype in Sharpin null mice. Both Sharpin/Fas and Sharpin/Fasl compound mutant mice developed an auto-inflammatory phenotype similar to that seen in Sharpin null mice, indicating that initiation of apoptosis by FAS signalling is likely not involved in the pathogenesis of this disease.

Indexed as

AnimalsApoptosisCarrier ProteinsFas Ligand Proteinfas ReceptorIntracellular Signaling Peptides and ProteinsKeratinocytesMiceSkin DiseasesTumor Necrosis Factor-alphaCarrier ProteinsFas Ligand Proteinfas ReceptorIntracellular Signaling Peptides and ProteinsSipl1 protein, mouseTumor Necrosis Factor-alphaapoptosiscpdmFasFaslSHARPIN

Identifiers

PMID28094869
PMCPMC5513782
OpenAlexW2577791040

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.